15,023 Shares in Neuronetics, Inc. $STIM Purchased by R Squared Ltd

R Squared Ltd acquired a new position in shares of Neuronetics, Inc. (NASDAQ:STIM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,023 shares of the company’s stock, valued at approximately $52,000.

Several other hedge funds have also bought and sold shares of STIM. Goldman Sachs Group Inc. boosted its stake in Neuronetics by 2,993.3% during the first quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock worth $2,320,000 after acquiring an additional 610,014 shares in the last quarter. Ghisallo Capital Management LLC bought a new stake in Neuronetics during the first quarter worth about $1,472,000. CenterBook Partners LP bought a new stake in Neuronetics during the first quarter worth about $1,200,000. Cubist Systematic Strategies LLC bought a new stake in Neuronetics during the first quarter worth about $1,055,000. Finally, AWM Investment Company Inc. bought a new stake in Neuronetics during the first quarter worth about $905,000. Institutional investors own 53.59% of the company’s stock.

Neuronetics Stock Up 5.4%

Shares of Neuronetics stock opened at $3.12 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.84 and a current ratio of 2.02. The stock has a market capitalization of $206.29 million, a PE ratio of -2.76 and a beta of 1.17. Neuronetics, Inc. has a 52-week low of $0.52 and a 52-week high of $5.92. The company has a 50-day simple moving average of $3.04 and a two-hundred day simple moving average of $3.63.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.07). Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. The company had revenue of $38.11 million for the quarter, compared to analysts’ expectations of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts anticipate that Neuronetics, Inc. will post -1.13 EPS for the current fiscal year.

Analysts Set New Price Targets

STIM has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a report on Saturday. Canaccord Genuity Group decreased their target price on shares of Neuronetics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.